Efflux pump gene amplifications bypass necessity of multiple target mutations for resistance against dual-targeting antibiotic

The rise of antimicrobial resistance has motivated the development of antibiotics that have multiple cellular targets, to theoretically reduce the frequency of resistance evolution, but adaptive trajectories and genetic determinants of resistance against such antibiotics are understudied. Here we investigate these in methicillin resistant Staphylococcus aureus (MRSA) using experimental evolution of ten independent populations in the presence of delafloxacin (DLX), a novel fluoroquinolone that targets both DNA gyrase and topoisomerase IV. We show that coding sequence mutations and genomic amplifications of the gene encoding a poorly characterized efflux pump, SdrM, lead to the evolution of high DLX resistance, circumventing the requirement for mutations in the target enzymes. Almost all of our evolved populations had one of two SdrM coding sequence mutations, which led to moderate DLX resistance. Additionally, these populations had 13 distinct genomic amplifications, each containing sdrM and two adjacent genes encoding efflux pumps, which resulted in up to 100-fold higher DLX resistance. While increased sdrM expression provided the selective advantage of the amplification in the DLX evolution, the adjacent efflux pumps hitchhiking in the genomic amplification contributed to cross-resistance against the aminoglycoside streptomycin. Finally, lack of sdrM necessitated mutations in both DNA gyrase and topoisomerase IV to evolve DLX resistance, and the presence of sdrM thus increased the frequency of resistance evolution. Our study highlights that instead of reduced rates of resistance, evolution of resistance to antibiotics with multiple cellular targets can involve alternate high-frequency evolutionary paths such as genomic amplifications of efflux pumps, that may cause unexpected alterations of the fitness landscape, including antibiotic cross-resistance.

[1]  J. Heddle,et al.  Gene amplifications cause high-level resistance against albicidin in Gram-negative bacteria , 2022, bioRxiv.

[2]  W. Roos,et al.  Teixobactin kills bacteria by a two-pronged attack on the cell envelope , 2022, Nature.

[3]  S. Satola,et al.  Heteroresistance via beta-lactamase gene amplification threatens the beta-lactam pipeline , 2022, bioRxiv.

[4]  Ying Li,et al.  Discovering interrelated natural mutations of efflux pump KmrA from Klebsiella pneumoniae that confer increased multidrug resistance , 2022, Protein science : a publication of the Protein Society.

[5]  M. Bhattacharyya,et al.  Efflux-linked Accelerated Evolution of Antibiotic Resistance at a Population Edge , 2022, bioRxiv.

[6]  Alan D. Lopez,et al.  Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis , 2022, The Lancet.

[7]  D. Hassabis,et al.  AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models , 2021, Nucleic Acids Res..

[8]  Melissa H. Brown,et al.  Efflux Pump Mediated Antimicrobial Resistance by Staphylococci in Health-Related Environments: Challenges and the Quest for Inhibition , 2021, Antibiotics.

[9]  Oriol Vinyals,et al.  Highly accurate protein structure prediction with AlphaFold , 2021, Nature.

[10]  Nadezhda T. Doncheva,et al.  The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets , 2020, Nucleic Acids Res..

[11]  C. Pál,et al.  Rational design of balanced dual-targeting antibiotics with limited resistance , 2020, PLoS biology.

[12]  R. MacLean,et al.  Efflux pump activity potentiates the evolution of antibiotic resistance across S. aureus isolates , 2020, Nature Communications.

[13]  W. Shafer,et al.  Cryo-EM Structures of a Gonococcal Multidrug Efflux Pump Illuminate a Mechanism of Drug Recognition and Resistance , 2020, mBio.

[14]  Maxwell Z. Wilson,et al.  A Dual-Mechanism Antibiotic Kills Gram-Negative Bacteria and Avoids Drug Resistance , 2020, Cell.

[15]  Prabasaj Paul,et al.  Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017. , 2020, The New England journal of medicine.

[16]  Narmada Thanki,et al.  CDD/SPARCLE: the conserved domain database in 2020 , 2019, Nucleic Acids Res..

[17]  D. Landman,et al.  Emergence of Delafloxacin-Resistant Staphylococcus aureus in Brooklyn, NY. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  D. Andersson,et al.  Mechanisms and clinical relevance of bacterial heteroresistance , 2019, Nature Reviews Microbiology.

[19]  Christian Lesterlin,et al.  Role of AcrAB-TolC multidrug efflux pump in drug-resistance acquisition by plasmid transfer , 2019, Science.

[20]  Sophie A Howard,et al.  Use of the counter selectable marker PheS* for genome engineering in Staphylococcus aureus. , 2019, Microbiology.

[21]  M. Vestergaard,et al.  Antibiotic Resistance and the MRSA Problem , 2019, Microbiology spectrum.

[22]  B. Levin,et al.  The high prevalence of antibiotic heteroresistance in pathogenic bacteria is mainly caused by gene amplification , 2019, Nature Microbiology.

[23]  G. Stein,et al.  Delafloxacin: A New Anti-methicillin-resistant Staphylococcus aureus Fluoroquinolone. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  E. Peterson,et al.  Antibiotic Resistance Mechanisms in Bacteria: Relationships Between Resistance Determinants of Antibiotic Producers, Environmental Bacteria, and Clinical Pathogens , 2018, Front. Microbiol..

[25]  M. Dunlop,et al.  Heterogeneity in efflux pump expression predisposes antibiotic-resistant cells to mutation , 2018, Science.

[26]  B. Luisi,et al.  Multidrug efflux pumps: structure, function and regulation , 2018, Nature Reviews Microbiology.

[27]  T. Park,et al.  Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa , 2018, Expert review of anti-infective therapy.

[28]  W. Reygaert An overview of the antimicrobial resistance mechanisms of bacteria , 2018, AIMS microbiology.

[29]  Jia Gu,et al.  fastp: an ultra-fast all-in-one FASTQ preprocessor , 2018, bioRxiv.

[30]  Jones K. Adjei,et al.  Modulation of antimicrobial efflux pumps of the major facilitator superfamily in Staphylococcus aureus , 2018, AIMS microbiology.

[31]  A. Oliver,et al.  Evolution of the Pseudomonas aeruginosa mutational resistome in an international Cystic Fibrosis clone , 2017, Scientific Reports.

[32]  D. Doyle,et al.  Efflux drug transporters at the forefront of antimicrobial resistance , 2017, European Biophysics Journal.

[33]  Q. C. Truong-Bolduc,et al.  Transcriptional Regulator TetR21 Controls the Expression of the Staphylococcus aureus LmrS Efflux Pump , 2017, Antimicrobial Agents and Chemotherapy.

[34]  F. J. Candel,et al.  Delafloxacin: design, development and potential place in therapy , 2017, Drug design, development and therapy.

[35]  P. Hall,et al.  Generation of a Stable Plasmid for In Vitro and In Vivo Studies of Staphylococcus Species , 2016, Applied and Environmental Microbiology.

[36]  Saeed Tavazoie,et al.  Multifactorial Competition and Resistance in a Two-Species Bacterial System , 2015, PLoS genetics.

[37]  T. Foster,et al.  Erratum for Monk et al., Complete Bypass of Restriction Systems for Major Staphylococcus aureus Lineages , 2016, mBio.

[38]  A. Ivens,et al.  A Novel Gene Amplification Causes Upregulation of the PatAB ABC Transporter and Fluoroquinolone Resistance in Streptococcus pneumoniae , 2015, Antimicrobial Agents and Chemotherapy.

[39]  Jun Lin,et al.  Mechanisms of antibiotic resistance , 2015, Front. Microbiol..

[40]  K. Lewis,et al.  A new antibiotic kills pathogens without detectable resistance , 2015, Nature.

[41]  E. Oldfield,et al.  Resistance-resistant antibiotics. , 2014, Trends in pharmacological sciences.

[42]  P. Tulkens,et al.  Comparison of the Antibiotic Activities of Daptomycin, Vancomycin, and the Investigational Fluoroquinolone Delafloxacin against Biofilms from Staphylococcus aureus Clinical Isolates , 2014, Antimicrobial Agents and Chemotherapy.

[43]  L. Piddock,et al.  Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. , 2014, Trends in microbiology.

[44]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[45]  Jeffrey E. Barrick,et al.  Identification of mutations in laboratory-evolved microbes from next-generation sequencing data using breseq. , 2014, Methods in molecular biology.

[46]  T. S. McConnell,et al.  Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. , 2012, The Journal of antimicrobial chemotherapy.

[47]  L. Fernández,et al.  Adaptive and Mutational Resistance: Role of Porins and Efflux Pumps in Drug Resistance , 2012, Clinical Microbiology Reviews.

[48]  S. V. van Hal,et al.  Predictors of Mortality in Staphylococcus aureus Bacteremia , 2012, Clinical Microbiology Reviews.

[49]  Marcel Martin Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[50]  Sanath H. Kumar,et al.  LmrS Is a Multidrug Efflux Pump of the Major Facilitator Superfamily from Staphylococcus aureus , 2010, Antimicrobial Agents and Chemotherapy.

[51]  A. Kwon,et al.  Extended Spectrum of Quinolone Resistance, Even to a Potential Latter Third-Generation Agent, as a Result of a Minimum of Two GrlA and Two GyrA Alterations in Quinolone-Resistant Staphylococcus aureus , 2010, Chemotherapy.

[52]  Diarmaid Hughes,et al.  Gene amplification and adaptive evolution in bacteria. , 2009, Annual review of genetics.

[53]  Linus Sandegren,et al.  Bacterial gene amplification: implications for the evolution of antibiotic resistance , 2009, Nature Reviews Microbiology.

[54]  H. Boucher,et al.  Epidemiology of methicillin-resistant Staphylococcus aureus. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[55]  Roberta B Carey,et al.  Invasive methicillin-resistant Staphylococcus aureus infections in the United States. , 2007, JAMA.

[56]  I. Chopra,et al.  Emergence and maintenance of resistance to fluoroquinolones and coumarins in Staphylococcus aureus: predictions from in vitro studies. , 2007, The Journal of antimicrobial chemotherapy.

[57]  R. Birch,et al.  The Phytotoxin Albicidin is a Novel Inhibitor of DNA Gyrase , 2007, Antimicrobial Agents and Chemotherapy.

[58]  D. Albertson,et al.  Gene amplification in cancer. , 2006, Trends in genetics : TIG.

[59]  T. Tsuchiya,et al.  Gene cloning and characterization of SdrM, a chromosomally-encoded multidrug efflux pump, from Staphylococcus aureus. , 2006, Biological & pharmaceutical bulletin.

[60]  M. Sasatsu,et al.  Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002. , 2005, International journal of antimicrobial agents.

[61]  Angela M. Nilius,et al.  In Vitro Antibacterial Potency and Spectrum of ABT-492, a New Fluoroquinolone , 2003, Antimicrobial Agents and Chemotherapy.

[62]  D. Ince,et al.  Topoisomerase Targeting with and Resistance to Gemifloxacin in Staphylococcus aureus , 2003, Antimicrobial Agents and Chemotherapy.

[63]  M. Sasatsu,et al.  Cloning and characterization of a novel chromosomal drug efflux gene in Staphylococcus aureus. , 2002, Biological & pharmaceutical bulletin.

[64]  D. Ince,et al.  Dual Targeting of DNA Gyrase and Topoisomerase IV: Target Interactions of Garenoxacin (BMS-284756, T-3811ME), a New Desfluoroquinolone , 2002, Antimicrobial Agents and Chemotherapy.

[65]  R. Lambert,et al.  Susceptibility testing: accurate and reproducible minimum inhibitory concentration (MIC) and non‐inhibitory concentration (NIC) values , 2000, Journal of applied microbiology.

[66]  K. Drlica,et al.  Mechanism of fluoroquinolone action. , 1999, Current opinion in microbiology.

[67]  H. Hiasa,et al.  DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities. , 1998, Biochimica et biophysica acta.

[68]  K. Köhrer,et al.  Characterization of grlA, grlB, gyrA, and gyrB Mutations in 116 Unrelated Isolates of Staphylococcus aureus and Effects of Mutations on Ciprofloxacin MIC , 1998, Antimicrobial Agents and Chemotherapy.

[69]  K. Hiramatsu,et al.  A point mutation in norA gene is responsible for quinolone resistance in Staphylococcus aureus. , 1990, Biochemical and biophysical research communications.

[70]  Jacques Monod,et al.  The genetic control and cytoplasmic expression of “Inducibility” in the synthesis of β-galactosidase by E. coli , 1959 .